| Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock |
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-05-16 14:01:09 |
Czytaj oryginał (ang.) |
| Amgen owes $406 million for monopolizing cholesterol drug market, US jury says |
A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's rival drug Praluent. |
reuters.com |
2025-05-15 20:57:21 |
Czytaj oryginał (ang.) |
| Stock Of The Day: Amgen Slips With Healthcare Sector, But Signals Point To A Reversal |
The stock of Amgen Inc. AMGN is trading higher on Thursday. But along with the rest of the healthcare sector, it is still in a steep downtrend. |
benzinga.com |
2025-05-15 19:25:17 |
Czytaj oryginał (ang.) |
| Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments |
Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market |
globenewswire.com |
2025-05-15 18:02:00 |
Czytaj oryginał (ang.) |
| Amgen Inc. (AMGN) BofA Securities 2025 Healthcare Conference (Transcript) |
Amgen Inc. (NASDAQ:AMGN ) BofA Securities 2025 Healthcare Conference Call May 14, 2025 12:20 PM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research and Development Conference Call Participants Tim Anderson - Bank of America Merrill Lynch Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. large pharma and biotech analyst at Bank of America. |
seekingalpha.com |
2025-05-14 20:21:22 |
Czytaj oryginał (ang.) |
| Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared |
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices. |
zacks.com |
2025-05-13 12:40:53 |
Czytaj oryginał (ang.) |
| Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices |
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices. |
youtube.com |
2025-05-12 16:36:24 |
Czytaj oryginał (ang.) |
| Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet |
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. |
seekingalpha.com |
2025-05-12 16:30:03 |
Czytaj oryginał (ang.) |
| Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs |
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug. |
zacks.com |
2025-05-12 14:41:06 |
Czytaj oryginał (ang.) |
| AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE |
THOUSAND OAKS, Calif. , May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. |
prnewswire.com |
2025-05-09 20:01:00 |
Czytaj oryginał (ang.) |
| Pressure is still on the pharma sector, says Mizuho's Jared Holz |
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector. |
youtube.com |
2025-05-08 23:23:04 |
Czytaj oryginał (ang.) |
| Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI |
Claremont, CA, May 08, 2025 (GLOBE NEWSWIRE) -- During the Keck Graduate Institute commencement ceremony on May 17, 2025, Robert A. Bradway will receive an honorary Doctor of Philosophy in Applied Life Sciences degree in recognition of his significant leadership contributions to the biotechnology field. |
globenewswire.com |
2025-05-08 15:00:00 |
Czytaj oryginał (ang.) |
| Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom |
CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the treatment of adult patients with moderate-to-severe Thyroid Eye Disease (TED). Affecting approximately 50,000 people in the UK,1 TED is a progressive and potentially vision-threatening condition, which can cause eye bulging, double vision, eye pain, r. |
businesswire.com |
2025-05-07 16:50:00 |
Czytaj oryginał (ang.) |
| Here's Why Amgen (AMGN) is a Strong Growth Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-05-07 14:51:18 |
Czytaj oryginał (ang.) |
| Here's Why Amgen (AMGN) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-05-06 14:46:28 |
Czytaj oryginał (ang.) |
| Amgen: Waiting Patiently For A Real Catalyst |
Amgen Inc.'s diversified portfolio ensures steady revenue but modest growth, with no single drug contributing more than 15% to total revenue. Recent revenue growth and margin upticks are promising, but sustainability remains uncertain amid biosimilar competition and pricing pressures. High debt levels and slow deleveraging, particularly from the Horizon Therapeutics acquisition, pose risks to future M&A and capital efficiency. |
seekingalpha.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Is Trending Stock Amgen Inc. (AMGN) a Buy Now? |
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-05-05 14:00:56 |
Czytaj oryginał (ang.) |
| AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales Growth |
AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter. |
zacks.com |
2025-05-05 13:05:37 |
Czytaj oryginał (ang.) |
| Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1 |
Amgen reported strong Q1 results with a 9% YoY revenue increase and a 24% rise in operating EPS, but shares dipped due to risk-on market sentiment. Despite competitive pressures and softer EPS trends, Amgen remains undervalued with a high dividend yield of 3.39% and robust free cash flow. Key risks include emerging therapies and macroeconomic factors, but positive Phase III data and new product launches support a buy-the-dip strategy. |
seekingalpha.com |
2025-05-04 14:30:00 |
Czytaj oryginał (ang.) |
| Dogs Of The Dow Chase May's 'Safer' Buy |
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding the single share price, supported by adequate free cash flow. Analyst projections suggest top Dow Dogs could net gains between 21.02% and 45.17% by May 2026, with an average net gain of 32.18%. 28 of 30 current Dow-listed stocks pay dividends. As of 5/1/25, the top ten ranged from 2.64%-6.26% by annual yield, and another top ten ranged from 18.06%-46.15% in broker-estimated target-price-upsides. |
seekingalpha.com |
2025-05-03 13:46:37 |
Czytaj oryginał (ang.) |
| Trade Tracker: Rob Sechan sells McDonald's and Vertex, buys Texas Pacific Land, Amgen and NRG |
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves. |
youtube.com |
2025-02-27 15:53:30 |
Czytaj oryginał (ang.) |
| Final Trades: Berkshire Hathaway, Amgen, Prologis and 3M |
The Investment Committee give you their top stocks to watch for the second half. |
youtube.com |
2025-02-27 15:53:17 |
Czytaj oryginał (ang.) |
| Amgen Stock: Why I Still Rate It A 'Buy' |
Amgen Stock: Why I Still Rate It A 'Buy' |
seekingalpha.com |
2025-02-26 14:31:50 |
Czytaj oryginał (ang.) |
| 10 Undervalued Dividend Growth Stocks: February 2025 |
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics. |
seekingalpha.com |
2025-02-25 11:00:00 |
Czytaj oryginał (ang.) |
| These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys? |
How is the Dow Jones Industrial Average (^DJI 0.08%) performing this year? It might depend on whether you view the proverbial glass of water as half-empty or half-full. |
fool.com |
2025-02-25 06:53:00 |
Czytaj oryginał (ang.) |
| Amgen plans $200 million investment in India site, CEO says |
U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert A. Bradway said at the inauguration of the site. |
reuters.com |
2025-02-24 03:28:40 |
Czytaj oryginał (ang.) |
| 4 Seniors & Aging Demographics Stocks to Watch Right Now |
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare. |
zacks.com |
2025-02-21 14:10:31 |
Czytaj oryginał (ang.) |
| Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock |
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2025-02-21 12:00:42 |
Czytaj oryginał (ang.) |
| Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript) |
Amgen, Inc. (NASDAQ:AMGN ) Citi's 2025 Virtual Oncology Leadership Summit Conference Call February 19, 2025 3:00 PM ET Company Participants Jean-Charles Soria - Senior Vice President of R&D Justin Claeys - Vice President of Investor Relations Conference Call Participants Geoffrey Meacham - Citigroup Geoffrey Meacham Hello, good afternoon. My name is Geoff Meacham. |
seekingalpha.com |
2025-02-20 00:46:04 |
Czytaj oryginał (ang.) |
| AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT |
THOUSAND OAKS, Calif. , Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. |
prnewswire.com |
2025-02-14 18:01:00 |
Czytaj oryginał (ang.) |
| Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript |
Amgen, Inc. (NASDAQ:AMGN ) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Company Participants Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - Head of Investor Relations Casey Capparelli - Investor Relations Conference Call Participants Jay Olson - Oppenheimer & Co. Jay Olson Hello, everyone. I'm Jay Olson, one of the biotech analysts at Oppenheimer, and it's a pleasure to welcome you to Oppenheimer's 35th Annual Healthcare Conference. |
seekingalpha.com |
2025-02-12 17:22:04 |
Czytaj oryginał (ang.) |
| Is Trending Stock Amgen Inc. (AMGN) a Buy Now? |
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2025-02-10 12:01:23 |
Czytaj oryginał (ang.) |
| Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move |
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities. |
fool.com |
2025-02-10 08:15:00 |
Czytaj oryginał (ang.) |
| 3 Fabulous Dividend Stocks to Buy in February |
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month. |
fool.com |
2025-02-09 16:30:00 |
Czytaj oryginał (ang.) |
| One 'Safer' Buy In 10 February Dogs Of The Dow |
Verizon is the only Dow Dog meeting the ideal of dividends from $1K invested exceeding single share price, supported by adequate free cash flow. Analysts project net gains of 15.23% to 33.94% for the top ten Dow Dogs by February 2026, with Merck leading at $376.03. Five stocks, including Verizon and Merck, are close to meeting the dogcatcher ideal, with prices within 67.5% of their annual dividends from $1K invested. |
seekingalpha.com |
2025-02-08 09:54:21 |
Czytaj oryginał (ang.) |
| AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE |
THOUSAND OAKS, Calif. , Feb. 7, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. |
prnewswire.com |
2025-02-07 18:01:00 |
Czytaj oryginał (ang.) |
| 23 Upcoming Dividend Increases, Including 2 Kings |
Excited to announce dividend hikes for 23 companies, including dividend kings SJW Group and California Water Service Group, with 5% and 7.1% increases. Companies with consistent dividend growth indicate financial health, attracting investors and boosting stock prices, leading to long-term wealth accumulation. Investment strategy focuses on stocks with rising dividends and outperforming benchmarks, using data from U.S. Dividend Champions and NASDAQ. |
seekingalpha.com |
2025-02-07 12:18:44 |
Czytaj oryginał (ang.) |
| Amgen: Multiple Strengths, But The Valuation Is A Concern |
Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as a hold due to its fair valuation and intense competition from biosimilars. Amgen's dividend yield remains attractive, supported by a 14-year streak of increases, a moderate payout ratio, and strong free cash flow. |
seekingalpha.com |
2025-02-07 06:11:19 |
Czytaj oryginał (ang.) |
| Amgen Stock Has Surged. Here's Where It's Headed Next. |
The stock is up 15% since late December. |
barrons.com |
2025-02-06 18:17:00 |
Czytaj oryginał (ang.) |
| Amgen: The Charts Didn't Lie, Upgrade To Buy |
Amgen is a "buy" due to its strong earnings beat, attractive dividend, and technical chart pattern forecasting positive future performance. I prioritize a balanced approach, focusing on risk and reward within a diversified portfolio, rather than relying solely on buy/sell/hold ratings, which I find to be misleading in many ways. AMGN's dividend safety and yield north of 3% make it appealing, despite concerns about valuation and growth. |
seekingalpha.com |
2025-02-06 17:39:35 |
Czytaj oryginał (ang.) |
| Big Blue Chip Dividends? Try These ‘Dogs' Up To 6.8% |
The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays. |
forbes.com |
2025-01-04 13:49:00 |
Czytaj oryginał (ang.) |
| Prediction: These 3 Healthcare Stocks Will Soar in 2025 |
No one knows for sure what the new year will hold for the market. However, some stocks' chances for success look particularly good. |
fool.com |
2025-01-04 08:48:00 |
Czytaj oryginał (ang.) |
| Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It |
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-01-03 12:01:40 |
Czytaj oryginał (ang.) |
| Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? |
The Dow Jones Industrial Average contains 30 handpicked companies that are, or at least once were, leaders in their respective industries. This makes the index an interesting hunting ground for high-yield stocks. |
fool.com |
2025-01-03 10:30:00 |
Czytaj oryginał (ang.) |
| Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields |
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. |
benzinga.com |
2025-01-03 09:39:42 |
Czytaj oryginał (ang.) |
| January Dow Dogs: 1 'Safer' Buy, And 5 With Promise |
Verizon Communications is the only Dow Dog meeting the ideal of annual dividends from $1K invested, exceeding the single share price. Analysts forecast 11.36% to 31.73% net gains from the top ten Dow Dogs by January 2026, with Merck leading at $313.37. A market correction of 82% could make all top ‘safer' Dow dividend dogs fair-priced, with dividends from $1K invested meeting or exceeding share prices. |
seekingalpha.com |
2025-01-02 14:21:43 |
Czytaj oryginał (ang.) |
| It Is Worth It to Buy the 3 Highest Paying Dividend Stocks in the Dow Jones? |
The Dow Jones Industrial Average has been considered a reliable snapshot reference for the health of American industry for over 130 years. |
247wallst.com |
2025-01-02 12:38:49 |
Czytaj oryginał (ang.) |
| Amgen stock price formed a death cross: will it rebound in 2025? |
The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After peaking at $341 in July, the stock plunged by over 25% to the current $260. |
invezz.com |
2025-01-02 03:01:00 |
Czytaj oryginał (ang.) |
| 2025's Five Highest Yielding Dogs of the Dow Could Explode Higher |
The ‘Dogs of the Dow' is a well-known strategy first published in 1991 by Michael Higgins. |
247wallst.com |
2025-01-01 10:08:10 |
Czytaj oryginał (ang.) |
| Amgen (AMGN) Advances While Market Declines: Some Information for Investors |
Amgen (AMGN) closed at $260.64 in the latest trading session, marking a +0.52% move from the prior day. |
zacks.com |
2024-12-31 20:55:39 |
Czytaj oryginał (ang.) |
| Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights |
Amgen (AMGN) closed at $259.30 in the latest trading session, marking a -1.28% move from the prior day. |
zacks.com |
2024-12-30 21:01:44 |
Czytaj oryginał (ang.) |
| Here's Why Amgen (AMGN) Gained But Lagged the Market Today |
The latest trading day saw Amgen (AMGN) settling at $264, representing a +0.24% change from its previous close. |
zacks.com |
2024-12-23 20:55:30 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know |
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2024-12-23 12:00:31 |
Czytaj oryginał (ang.) |
| 2 Excellent Dividend Stocks to Buy on the Dip |
AbbVie (ABBV 2.37%) and Amgen (AMGN 0.84%) have a lot in common. They are both leading drugmakers and have strong dividend track records. |
fool.com |
2024-12-23 06:32:00 |
Czytaj oryginał (ang.) |
| What's Going On With Amgen Stock On Friday? |
On Friday, Novo Nordisk A/S NVO released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program. |
benzinga.com |
2024-12-20 16:40:50 |
Czytaj oryginał (ang.) |
| Dow Losing Streak Longest in 50 Years: Grab These Bargain Blue-Chip Dividend Stocks Now |
The Dow Jones industrial average is a price-weighted index of 30 blue-chip U.S. |
247wallst.com |
2024-12-19 10:46:33 |
Czytaj oryginał (ang.) |
| PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises |
LONDON--(BUSINESS WIRE)---- $AMGN #biotech--PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQ: SLXN). The precision oncology sector has rapidly evolved into one of the most dynamic areas of cancer treatment innovation. Among the key players pioneering novel approaches is Silexion Therapeutics, a clinical-stage biotechnology company focused on RNA interference (RNAi) therapies for KRAS-driven cancers—one of the most prevalent and historically “undruggable” oncogenic drivers. Silexion'. |
businesswire.com |
2024-12-17 11:36:00 |
Czytaj oryginał (ang.) |
| Should You Buy the 3 Highest Yielding Dividend Stocks in the Dow Jones? |
The Dow Jones is one of Wall Street's most iconic benchmarks and it tracks 30 of America's largest companies. |
247wallst.com |
2024-12-17 10:58:21 |
Czytaj oryginał (ang.) |
| Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease |
Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell. The post Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease appeared first on Investor's Business Daily. |
investors.com |
2024-12-16 11:28:42 |
Czytaj oryginał (ang.) |
| Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value |
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "Magic Formula" and James O'Shaughnessy's methodologies to screen stocks based on earnings yield and return on total capital. Exclude overly regulated sectors like Utilities, Financials, and REITs to focus on sectors with higher growth potential and less regulatory constraints. |
seekingalpha.com |
2024-12-14 01:54:16 |
Czytaj oryginał (ang.) |